435results about How to "Efficient induction" patented technology

A heat treatment jig for supporting silicon semiconductor substrates by contacting, being loaded onto a heat treatment boat in a vertical heat treatment furnace, comprises; the configuration of a ring or a disc structure with the wall thickness between 1.5 and 6.0 mm; the deflection displacement of 100 μm or less at contact region in loaded condition; the outer diameter which is 65% or more of the diameter of said substrate; and the surface roughness (Ra) of between 1.0 and 100 μm at the contact region. The use of said jig enables to effectively retard the slip generation and to avoid the growth hindrance of thermally oxidized film at the back surface of said substrate, diminishing the surface steps causing the defocus in photolithography step in device fabrication process, thereby enabling to maintain high quality of silicon semiconductor substrates and to substantially enhance the device yield.

Disclosed herein are methods for inducing an immunological CTL response to an antigen by sustained, regular delivery of the antigen to a mammal so that the antigen reaches the lymphatic system. Antigen is delivered at a level sufficient to induce an immunologic CTL response in a mammal and the level of the antigen in the mammal's lymphatic system is maintained over time sufficient to maintain the immunologic CTL response. Also disclosed is an article of manufacture for delivering an antigen that induces a CTL response in an animal.

The preferred embodiment of the invention contemplates a device configured to prepare and deploy a resilient sleeve on to a portion of body tissue. The device expands the resilient sleeve, uses a vacuum system to draw the body tissue in to the resilient sleeve, and releases the resilient sleeve from the expanded state so that it captures and constricts the body tissue.

An organic electroluminescence device including at least an anode, an emitting layer, an electron-transporting region and a cathode in sequential order, wherein the emitting layer contains a host and a dopant which gives fluorescent emission of which the main peak wavelength is 550 nm or less; the affinity Ad of the dopant is equal to or larger than the affinity Ah of the host; the triplet energy E^T_d of the dopant is larger than the triplet energy E^T_b of the host; and a blocking layer is provided within the electron-transporting region such that it is adjacent to the emitting layer, and the triplet energy E^T_b of the blocking layer is larger than E^T_h.

The present invention provides a novel method for inducing antigen-specific T cells. A method for inducing antigen-specific T cells in a patient comprising administering to said patient in need thereof composition (a) which comprises a therapeutically effective amount of an antigen protein or an antigen peptide as an active ingredient, and composition (b) which comprises a therapeutically effective amount of a cell wall skeleton integrant of the BCG strain of Mycobacterium bovis as an active ingredient, wherein composition (b) is administered in advance and then composition (a) is administered, and related pharmaceutical compositions are provided.

The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular an Aβ1-6 peptide-VLP-composition. More specifically, the invention provides a composition comprising a virus-like particle and at least one Aβ1-6 peptide bound thereto. The invention also provides a process for producing the conjugates and the ordered and repetitive arrays, respectively. The compositions of the invention are useful in the production of vaccines for the treatment of Alzheimer's disease and as a pharmaccine to prevent or cure Alzheimer's disease and to efficiently induce immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.

The slow kinetics and low efficiency of reprogramming methods to generate human induced pluripotent stem cells (iPSCs) impose major limitations on their utility in biomedical applications. Here we describe a chemical approach that dramatically improves (>200 fold) the efficiency of iPSC generation from human fibroblasts, within seven days of treatment. This will provide a basis for developing safer, more efficient, non-viral methods for reprogramming human somatic cells.

The invention provides a vaccine composition containing an antigen for inducing cellular immunity, comprising at least one first cellular immunity induction promoter.

The present invention is directed to an artificial nucleic acid and to polypeptides suitable for use in treatment or prophylaxis of an infection with Norovirus or a disorder related to such an infection. In particular, the present invention concerns a Norovirus vaccine. The present invention is directed to an artificial nucleic acid, polypeptides, compositions and vaccines comprising the artificial nucleic acid or the polypeptides. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptides, compositions and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the artificial nucleic acid, polypeptides, compositions and vaccines.

PCT No. PCT/DK96/00158 Sec. 371 Date Nov. 26, 1997 Sec. 102(e) Date Nov. 26, 1997 PCT Filed Apr. 1, 1996 PCT Pub. No. WO96/30394 PCT Pub. Date Oct. 3, 1996The invention relates to the technical application of electromagnetic radiation such as microwaves and radiowaves and application of ultra sound to chain molecules. In particular, the present invention relates to the utilization of topological excitations such as wring, twist and torsional modes, e.g., for generating structure, such as in folding, refolding or renaturation, and denaturation or unfolding of peptides, polypeptides, proteins, and enzymes; for generating changes in molecular affinity; for stimulating drug receptor interactions; and for changing molecular communication, is described. The technique is based on a new understanding of the underlying physical phenomenon and can also be applied to other chain molecules and biologically active biomolecules and tailored polymers such as glucoproteins, antibodies, genomic chain molecules such as DNA and RNA as well as PNA, carbohydrates, and synthetic and natural organic polymers. The invention is especially applicable for solving problems related to inclusion bodies and aggregation when using recombinant DNA and protein engineering techniques. Furthermore, the invention can be utilized in therapeutic treatment and in development and production of pharmaceuticals. The area of applicability ranges from biotechnological industry, food industry, drug industry, pharmacological industry, chemical industry, and concerns, e.g., the treatment of conditions and diseases related to influenza, hepatitis, polio, malaria, borrelia, diabetes, Alzheimer's disease, Creutzfeldt Jakob disease, other prion related diseases, multiple sclerosis, cataract, heart diseases, cancer, and aging.

The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular an array comprising a protein or peptide of IL-5, IL-13 or eotaxin. More specifically, the invention provides a composition comprising a virus-like particle and at least one protein, or peptide of IL-5, IL-13 and/or eotaxin bound thereto. The invention also provides a process for producing the conjugates and the ordered and repetitive arrays, respectively. The compositions of the invention are useful in the production of vaccines for the treatment of allergic diseases with an eosinophilic component and as a pharmaccine to prevent or cure allergic diseases with an eosinophilic component and to efficiently induce immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.

An intraorally administrable vaccine composition useful to be a preventive or therapeutic agent for infectious diseases, and effectively induces a systemic immune response or a mucosal immune response is provided. A vaccine composition for administration to the oral cavity of a human or an animal, the vaccine composition containing at least one antigen derived from an infectious disease, and at least one selected from the group consisting of a toll-like receptor 4 (TLR4) agonist, a toll-like receptor 2/6 (TLR2/6) agonist, and cyclic dinucleotide, or a derivative or salt thereof.

A perpendicular magnetic recording head includes a first magnetic portion, a second magnetic portion formed with a gap from the first magnetic portion, and a coil layer located in the gap between the first magnetic portion and the second magnetic portion for applying a recording magnetic field to the first magnetic field and the second magnetic field. The yoke layer is formed on the second magnetic portion, a width whose direction is orthogonal to the height direction of a front end of the yoke layer becomes larger gradually or continuously as going in the height direction, and the width becomes larger gradually or continuously as going farther from the second magnetic portion.

Disclosed is a nozzle assembly comprising a nozzle housing and a valve element axially slidable therewithin between a closed and an open position. The nozzle housing has a housing inlet and a housing outlet fluidly interconnected by a plurality of housing passages. The valve element has a truncated conical valve body including a conical outer surface and a concave inner surface with a plurality of valve apertures extending through the valve body. The outer surface is sealingly engagable to a valve seat formed in the housing outlet such that the flow of cooling water through the valve apertures is prevented when the valve element is in the closed position. The outer surface and valve seat collectively define an annular gap when the valve element is axially displaced to the open position such that a portion of the cooling water flowing through the annular gap may pass through the valve apertures.